Cargando…

Systematic Evaluation of Randomized Clinical Trials of Huangqin Tang in Combination with Mesalazine for Ulcerative Colitis

OBJECTIVE: To systematically evaluate the efficacy and safety of Huangqin Tang (HQT) combined with mesalazine for the treatment of ulcerative colitis (UC). METHODS: The China Knowledge Network, Wanfang Data, VIP, PubMed, SinoMed, Embase, and Cochrane Library databases were searched for randomized co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pan, Chengyu, Liu, Mengru, Li, Hui, Wei, Lanfu, Wang, Pengcheng, Wu, Kexuan, Ji, Xing, Gu, Limei, Tian, Yaozhou
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9388247/ https://www.ncbi.nlm.nih.gov/pubmed/35990830 http://dx.doi.org/10.1155/2022/2175913

Ejemplares similares

Huangqin-Tang and Ingredients in Modulating the Pathogenesis of Ulcerative Colitis
por: Wang, Chunyan, et al.
Publicado: (2017)

Effect of Huangqin Tang on Colonic Gene Expression in Rats with Ulcerative Colitis
por: Wang, Dunfang, et al.
Publicado: (2020)

Effect of Huangqin Tang on Urine Metabolic Profile in Rats with Ulcerative Colitis Based on UPLC-Q-Exactive Orbitrap MS
por: Wang, Dunfang, et al.
Publicado: (2020)

Huangqin-Tang Ameliorates TNBS-Induced Colitis by Regulating Effector and Regulatory CD4(+) T Cells
por: Zou, Ying, et al.
Publicado: (2015)

Research on the Protective Effect of MiR-185-3p Mediated by Huangqin-Tang Decoction (HQT) on the Epithelial Barrier Function of Ulcerative Colitis
por: Changlin, Zhou, et al.
Publicado: (2021)

Huangqin Tang Interference With Colitis Associated Colorectal Cancer Through Regulation of Epithelial Mesenchymal Transition and Cell Cycle
por: Ma, Xuran, et al.
Publicado: (2022)

Mesalazine-induced myopericarditis in a patient with ulcerative colitis
por: Asadi, Jalal, et al.
Publicado: (2017)

Recurrent Mesalazine-Induced Myopericarditis in a Patient with Ulcerative Colitis
por: Park, Eun Hye, et al.
Publicado: (2012)

Protective effects of Huangqin Decoction against ulcerative colitis and associated cancer in mice
por: Chen, Gang, et al.
Publicado: (2016)

Transcriptomics and experimental validation-based approach to understand the effect and mechanism of Huangqin tang interfeience with colitis associated colorectal cancer
por: Ma, Xuran, et al.
Publicado: (2023)

Mesalazine-Induced Interstitial Nephritis in a Patient With Ulcerative Colitis
por: da Cunha Marques, José, et al.
Publicado: (2022)

Efficacy of Combined Mesalazine Plus Corticosteroid Enemas for Diversion Colitis after Subtotal Colectomy for Ulcerative Colitis
por: Matsumoto, Satohiro, et al.
Publicado: (2016)

Huangqin-tang ameliorates dextran sodium sulphate-induced colitis by regulating intestinal epithelial cell homeostasis, inflammation and immune response
por: Zou, Ying, et al.
Publicado: (2016)

Combined Diosmectite and Mesalazine Treatment for Mild-to-Moderate Ulcerative Colitis: A Randomized, Placebo-Controlled Study
por: Jiang, Xue-Liang, et al.
Publicado: (2015)

Efficacy of oral prolonged‐release mesalazine in moderately active ulcerative colitis
por: Paridaens, Kristine, et al.
Publicado: (2023)

Efficacy and safety of low-dose thalidomide combined with mesalazine in the treatment of refractory ulcerative colitis in adults
por: Chen, Jun-Rong, et al.
Publicado: (2022)

Integrated bioinformatics and network pharmacology to identify the therapeutic target and molecular mechanisms of Huangqin decoction on ulcerative Colitis
por: Wu, Yi, et al.
Publicado: (2022)

Crohn's Disease with Mesalazine Allergy that Was Difficult to Differentiate from Comorbid Ulcerative Colitis
por: Tsuboi, Rumiko, et al.
Publicado: (2018)

The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis
por: Yuichiro, Ohtaki, et al.
Publicado: (2022)

Integrated Analysis Reveals the Targets and Mechanisms in Immunosuppressive Effect of Mesalazine on Ulcerative Colitis
por: Li, Rong, et al.
Publicado: (2022)

Mesalazine granules promote disease clearance in patients with mild‐to‐moderate ulcerative colitis
por: Kruis, Wolfgang, et al.
Publicado: (2023)

Comparison of efficacies of once-daily dose multimatrix mesalazine and multiple-dose mesalazine for the maintenance of remission in ulcerative colitis: a randomized, double-blind study
por: Ogata, Haruhiko, et al.
Publicado: (2017)

Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis
por: Kamm, M A, et al.
Publicado: (2008)

Acute Pancreatitis due to pH-Dependent Mesalazine That Occurred in the Course of Ulcerative Colitis
por: Arai, Yoshinori, et al.
Publicado: (2011)

Mesalazine-related lung disease in a patient with ulcerative colitis: A case report
por: Huang, Po-Han, et al.
Publicado: (2018)

Correction: The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis
por: Ohtaki, Yuichiro, et al.
Publicado: (2023)

Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients
por: Yagisawa, Keiji, et al.
Publicado: (2019)

Flavonoid profiling of a traditional Chinese medicine formula of Huangqin Tang using high performance liquid chromatography
por: Li, Tao, et al.
Publicado: (2016)

The effects of crocin, mesalazine and their combination in the acetic acid-induced colitis in rats
por: Faramarzpour, Amir, et al.
Publicado: (2019)

Gancao Xiexin decoction combined with mesalazine in the treatment of ulcerative colitis: A protocol for a systematic review and meta-analysis
por: Zhong, Chun, et al.
Publicado: (2020)

Radix Scutellariae — Huangqin
por: Wagner, Hildebert, et al.
Publicado: (2011)

Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine
por: Prenzler, Anne, et al.
Publicado: (2011)

Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis
por: Böhm, Stephan Karl, et al.
Publicado: (2014)

Mesalazine treatment causing resolution of intracranial hypertension secondary to ulcerative colitis: A case report
por: Khanna, Raoul Kanav, et al.
Publicado: (2018)

Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial
por: Rubin, David T., et al.
Publicado: (2016)

Comparison of efficacy of multimatrix mesalazine 4.8 g/day once-daily with other high-dose mesalazine in active ulcerative colitis: a randomized, double-blind study
por: Ogata, Haruhiko, et al.
Publicado: (2017)

Corrigendum: Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients
por: Yagisawa, Keiji, et al.
Publicado: (2020)

Efficacy of Long-Term 4.0 g/Day Mesalazine (Pentasa) for Maintenance Therapy in Ulcerative Colitis
por: Takeshima, Fuminao, et al.
Publicado: (2014)

Is once daily multimatrix mesalazine therapy effective regardless of the dose in patients with mild to moderate ulcerative colitis?
por: Jeon, Seong Ran
Publicado: (2018)

Comparative Transcriptomic Analysis Reveals the Immunosuppressive Targets of Mesalazine in Dextran Sulfate Sodium-Induced Ulcerative Colitis
por: Li, Rong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n1r1smr7lhpbshijbf9gntkj57